Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Bladder Bank (a Prospective Banking Study)

NCT ID: NCT06109857Sponsor: Mayo ClinicLast updated: 2026-03-16

Summary

This study collects blood and urine samples from patients with bladder cancer to support the development of tests for early detection of bladder cancer.

Detailed description

PRIMARY OBJECTIVE: I. To establish a biobank of samples (blood and urine) to support the development of non-invasive tests for early detection of bladder cancer. OUTLINE: This is an observational study. Patients undergo blood and urine sample collection and have their medical records reviewed while on study.

Arms & interventions

  • OtherNon-Interventional Study

    Non-interventional study

Outcome measures

Primary

  • Blood sample to support the development of non-invasive tests for early detection of bladder cancer

    At study enrollment for subjects, 60 ml (4 tablespoons) of blood will be drawn from all participants and processed according to standardized study biospecimen protocol. All samples will be stored for future analysis in Molecular Cancer Diagnostic Laboratory at Mayo Clinic.

    Time frame: Baseline (at enrollment)

  • Urine sample to support the development of non-invasive tests for early detection of bladder cancer

    At study enrollment for subjects, up to 20mL of urine will be collected from the same or unique case patients identified for blood collection. All samples will be stored for future analysis in Molecular Cancer Diagnostic Laboratory at Mayo Clinic.

    Time frame: Baseline (at enrollment)

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Age \> 18 years * Patient has undergone office-based evaluation for hematuria \[computed tomography (CT), ultrasound, cystoscopy\] Exclusion Criteria: * Patient has known cancer outside of the target cancer 5 years prior to current collection (not including basal cell or squamous cell skin cancers; if patient has not been seen or if information is not available, the patient is eligible) * Patient has recurrent muscle invasive bladder cancer * Patient has ever been previously diagnosed with UTUC (upper tract urothelial carcinoma) prior to bladder resection * Patient has received chemotherapy class drugs for the treatment of non-target origin cancer in the 5 years prior to current collection * Patient has had any prior radiation therapy to the target lesion prior to current collection * Patient has had a biopsy to the target organ and/or lesion within 3 days before collection * Patient has undergone cystectomy or cystoprostatectomy * Patient has transurethral instrumentation (placement of urinary catheter) within 7 days prior to urine collection * Patient has had a urinary tract infection within 14 days prior to urine collection * Patient has chronic indwelling urinary catheter

Study locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

Recruiting
Clinical Trials Referral Office · Contact
John B. Kisiel, MD · Principal Investigator
Bladder Bank (a Prospective Banking Study) | Cancerify